New functionality advances optimization of workflow and enhances dose management to improve quality, efficiency and compliance
INDIANOLA, Pa.–(BUSINESS WIRE)–Bayer Radiology is announcing Radimetrics® v3.0, the newest evolution of its enterprise dose management application. The newly designed system supports many of the latest accreditation standards on dose reporting and tracking, protocol management, and benchmarking, along with offering the latest in cyber security.
Radimetrics 3.0 helps patient-care teams report, track, and manage radiation dose and contrast dose throughout the chain of care with increased functionality and features, including:
– Upgraded front-end user interface for easier navigation and optimization of workflow
– Easy visualization and expanded dose analytics; including new summary page library to intuitively establish benchmarks and inform point-of care decisions
– Data tracking to improve billing processes
– Enhanced alerting notifications of outlier data and consolidation of dose reference levels to help users advance patient safety measures
– Virtual CE training modules (ASRT accredited)
– Positioned for future innovations including expanded Fluoroscopy capabilities, cloud-based deployments, enhanced benchmarking and AI insights
“The advancement in the design and functional improvement in workflow was positively received throughout our human factors design analysis with Radimetrics 3.0 users,” said Adam Czibur, Bayer Senior Factors Engineer. “Following their testing experience, users described their experience as quicker, easier to navigate and providing workflow flexibility, and reported higher levels of usability and comfortability compared to Radimetrics v2.x”.
In addition, Radimetrics v3.0 leverages HTML5 standards to address the latest cyber security updates, and provide protection against future vulnerabilities, while addressing the obsolescence of Adobe Flash technology. The conversion to HTML5 prepares our Radimetrics customers for future cloud configurations, AI solutions, and new injector platforms.
“The launch of Radimetrics represents an important advancement in utilizing digital platforms for analyzing data to optimize standardization, and problem-solve in real time,” said Dennis Durmis, Head of Radiology Americas, “Its specialty focused interface design, new capabilities, and comprehensive training approach, will drive standardization for personalized care for patients.”
Bayer is a worldwide leading provider of medical devices and services, providing customers with innovative products, on-site applications support and unmatched equipment service.
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to www.bayer.us.
Bayer® and the Bayer Cross® are registered trademarks of Bayer.
Intended for U.S. Media Only
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
PP-RADI-US-0346-1 December 2020